GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised
Gilead Sciences (GILD) reported Q2 2026 adjusted loss of $6.75 per share, narrower than the $7.07 Zacks estimate, driven by large acquisition-related IPR&D charges. Revenues rose 10% to $7.80B, beating $7.37B. HIV sales grew, Trodelvy rose 26% to $457M, and Gilead raised 2026 product sales guidance; Veklury outlook lowered to ~$300M.
How this was made
The 30-second read
Why it matters
Traders should focus on the raised 2026 product sales range, the upgraded HIV sales growth outlook (9-10%), and the updated Veklury outlook, while monitoring cell-therapy decline guidance and the EVOKE-03 discontinuation as downside catalysts.
Market read
This is a guidance-up earnings update with multiple product-level datapoints (Biktarvy, Descovy, Yeztugo, Trodelvy) and explicit full-year outlook changes.
What to watch
Trodelvy growth is supported by new approvals, but EVOKE-03 discontinuation in lung cancer signals potential execution risk in combination regimens.
Background
Gilead’s Q2 included significant acquisition-related accounting charges tied to Arcellx, Tubulis, and Ouro Medicines, while operating performance was driven by HIV and Trodelvy.
Ticker impact
Gilead beat Q2 adjusted loss and revenue, raised 2026 product sales and HIV growth guidance, and reported Yeztugo and Trodelvy momentum.
Bullish bias for near-term positioning as guidance upgrades and HIV/PrEP uptake support estimates, partially tempered by cell-therapy decline and EVOKE-03 discontinuation.
The article discloses multiple decision-grade updates: Q2 results, raised full-year product sales and HIV growth guidance, Yeztugo sales expectations, and a specific EVOKE-03 discontinuation risk.
Market effects
Reinforces investor focus on HIV franchise durability and PrEP expansion, while highlighting ongoing competitive pressure in cell therapy.
Limited direct regional read-through; FDA and European approvals can influence global biotech sentiment.
Supports broader pharma sentiment around HIV and oncology pipeline execution, with regulatory milestones in the US and Europe.
Counterpoint
The headline beat is partly distorted by large acquisition-related IPR&D charges; base-business strength may not fully offset longer-term oncology/cell-therapy competitive erosion.
Key entities
- public_companyGilead Sciences, Inc.
Reported Q2 results, raised 2026 product sales and HIV growth guidance, and updated outlook for HIV, Trodelvy, cell therapy, and Veklury.
- drugYeztugo (lenacapavir)
Reported Q2 sales of $232 million and management expects about $1 billion in 2026; FDA accepted supplemental NDA for once-weekly oral PrEP.
- drugTrodelvy
Reported 26% YoY Q2 sales growth to $457 million and received first-line mTNBC approvals; EVOKE-03 in lung cancer was discontinued.
- partnerMerck
Partnered on Trodelvy studies and is referenced in combination/regimen approvals and the EVOKE-03 discontinuation.
